Molecularly targeted therapies for nonmelanoma skin cancers

International Journal of Dermatology

Volumn 52, Issue 6, 2013, Pages 654-665

  Liu, Lucinda S ^a   Colegio, Oscar R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; IMATINIB; LAPATINIB; RAPAMYCIN; VEMURAFENIB; VIMENTIN; VISMODEGIB;

ACNE; ADVERSE DRUG REACTION; ALOPECIA; ANGIONEUROTIC EDEMA; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELLULITIS; DEPIGMENTATION; DERMATITIS; DERMATOFIBROSARCOMA PROTUBERANS; DESQUAMATION; DIAPHORESIS; ECCHYMOSIS; EDEMA; ERYTHEMA; EXCISION; FACE EDEMA; FOLLICULITIS; GENE AMPLIFICATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH CARE QUALITY; HEDGEHOG; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HOT FLUSH; HUMAN; HYPOPIGMENTATION; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LICHENOID ERUPTION; LUNG NON SMALL CELL CANCER; MEDULLOBLASTOMA; MISSENSE MUTATION; MOLECULARLY TARGETED THERAPY; MOUTH ULCER; MULTIMODALITY CANCER THERAPY; NAIL DISEASE; NONHUMAN; PATHOGENESIS; PERIPHERAL EDEMA; PETECHIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; PRURITUS; PURPURA; RASH; REVIEW; SIDE EFFECT; SKIN CARCINOMA; SKIN FISSURE; SKIN ULCER; STEADY STATE; STEVENS JOHNSON SYNDROME; STOMATITIS; SUPPURATIVE HIDRADENITIS; WART VIRUS; XEROSIS;

ANILIDES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BENZAMIDES; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DERMATOFIBROSARCOMA; HUMANS; PIPERAZINES; PYRIDINES; PYRIMIDINES; SARCOMA, KAPOSI; SIROLIMUS; SKIN NEOPLASMS;

EID: 84878142672     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12017     Document Type: Review

References (93)

1. Jacob A. Observations respecting an ulcer of peculiar character, which attacks the eyelids and other parts of the face. Dublin Hosp Rep Commun Med Surg 1827; 4: 232-239.
2. Chen JG, Fleischer AB Jr, Smith ED, et al. Cost of non-melanoma skin cancer treatment in the United States. Dermatol Surg 2001; 27: 1035-1038.
3. Lear JT, Tan BB, Smith AG, et al. Risk factors for basal cell carcinoma in the UK: case-control study in 806 patients. J R Soc Med 1997; 90: 371-374.
4. Goto M, Kai Y, Arakawa S, et al. Analysis of 256 cases of basal cell carcinoma after either one-step or two-step surgery in a Japanese institution. J Dermatol 2012; 39: 68-71.
5. Kyrgidis A, Vahtsevanos K, Tzellos TG, et al. Clinical, histological and demographic predictors for recurrence and second primary tumors of head and neck basal cell carcinoma. A 1062-patient cohort study from a tertiary cancer referral hospital. Eur J Dermatol 2010; 20: 276-282.
6. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008; 8: 743-754.
7. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol 2006; 2: 127-147.
8. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85: 841-851.
9. Gailani MR, Bale SJ, Leffell DJ, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 1992; 69: 111-117.
10. Nusslein-Volhard C, Wieschaus E. Mutations affecting segment number and polarity in Drosophila. Nature 1980; 287: 795-801.
11. McMahon AP, Ingham PW, Tabin CJ. Developmental roles and clinical significance of hedgehog signaling. Curr Top Dev Biol 2003; 53: 1-114.
12. Paladini RD, Saleh J, Qian C, et al. Modulation of hair growth with small molecule agonists of the hedgehog signaling pathway. J Invest Dermatol 2005; 125: 638-646.
13. Aszterbaum M, Rothman A, Johnson RL, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol 1998; 110: 885-888.
14. Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998; 58: 1798-1803.
15. Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal cell carcinoma. Nature 1998; 391: 90-92.
16. Reifenberger J, Wolter M, Knobbe CB, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005; 152: 43-51.
17. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homolog of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996; 14: 78-81.
18. Ng JM, Curran T. The hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer 2011; 11: 493-501.
19. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. N Engl J Med 2009; 361: 1164-1172.
20. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 362: 1173-1178.
21. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326: 572-574.
22. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011; 131: 1735-1744.
23. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different longterm immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177-186.
24. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691.
25. Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous cell carcinoma: a prospective study. Lancet Oncol 2008; 9: 713-720.
26. Cherpelis BS, Marcusen C, Lang PG. Prognostic factors for metastasis in squamous cell carcinoma of the skin. Dermatol Surg 2002; 28: 268-273.
27. Jambusaria-Pahlajani A, Hess SD, Katz KA, et al. Uncertainty in the perioperative management of high-risk cutaneous squamous cell carcinoma among Mohs surgeons. Arch Dermatol 2010; 146: 1225-1231.
28. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26: 976-990.
29. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the veterans affairs topical tretinoin chemoprevention trial. Cancer 2009; 115: 2523-2530.
30. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: 23-24.
31. Campbell C, Quinn AG, Ro YS, et al. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J Invest Dermatol 1993; 100: 746-748.
32. Jiang W, Ananthaswamy HN, Muller HK, et al. p53 protects against skin cancer induction by UV-B radiation. Oncogene 1999; 18: 4247-4253.
33. Arron ST, Ruby JG, Dybbro E, et al. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol 2011; 131: 1745-1753.
34. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109: 157-162.
35. Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther 2011; 11: 777-792.
36. Maubec E, Duvillard P, Velasco V, et al. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 2005; 25: 1205-1210.
37. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24: 4170-4176.
38. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007; 25: 2164-2170.
39. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 4: 9-15.
40. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007; 13: 1552-1561.
41. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127.
42. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011; 29: 3419-3426.
43. Gloster HM Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996; 35: 355-374.
44. Bowne WB, Antonescu CR, Leung DH, et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000; 88: 2711-2720.
45. Bendix-Hansen K, Myhre-Jensen O, Kaae S. Dermatofibrosarcoma protuberans. A clinico-pathological study of nineteen cases and review of world literature. Scand J Plast Reconstr Surg 1983; 17: 247-252.
46. Criscione VD, Weinstock MA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007; 56: 968-973.
47. Chuang TY, Su WP, Muller SA. Incidence of cutaneous T cell lymphoma and other rare skin cancers in a defined population. J Am Acad Dermatol 1990; 23: 254-256.
48. Aiba S. Dermatofibrosarcoma protuberans expresses CD34. J Am Acad Dermatol 1994; 30: 508.
49. Kutzner H. Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue. J Am Acad Dermatol 1993; 28: 613-617.
50. Haycox CL, Odland PB, Olbricht SM, et al. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment. J Am Acad Dermatol 1997; 37: 438-444.
51. Lemm D, Mugge LO, Mentzel T, et al. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 2009; 135: 653-665.
52. Stranahan D, Cherpelis BS, Glass LF, et al. Immunohistochemical stains in Mohs surgery: a review. Dermatol Surg 2009; 35: 1023-1034.
53. Galimberti G, Montano AP, Kowalczuk A, et al. Outcomes in 11 patients with dermatofibrosarcoma protuberans treated with Mohs micrographic surgery. Int J Dermatol 2012; 51: 89-93.
54. Sirvent N, Maire G, Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosom Cancer 2003; 37: 1-19.
55. Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.
56. Shimizu A, O'Brien KP, Sjoblom T, et al. The dermatofibrosarcoma protuberans associated collagen type I alpha-1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999; 59: 3719-3723.
57. Giacchero D, Maire G, Nuin PA, et al. No correlation between the molecular subtype of COLIA1-PDGFB fusion gene and the clinico-histopathological features of dermatofibrosarcoma protuberans. J Invest Dermatol 2010; 130: 904-907.
58. Marx J. Molecular biology. Cancer fighter's modus operandi revealed. Science 2000; 289: 1857-1859.
59. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
60. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938-1942.
61. Sjoblom T, Shimizu A, O'Brien KP, et al. Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 2001; 61: 5778-5783.
62. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two Phase II clinical trials. J Clin Oncol 2010; 28: 1772-1779.
63. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol 2005; 23: 866-873.
64. Amitay-Laish I, Stemmer SM, Lacouture ME. Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther 2011; 24: 386-395.
65. Vaidya S, Ghosh K, Vundinti BR. Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review. Eur J Haematol 2011; 87: 381-393.
66. Stacchiotti S, Pedeutour F, Negri T, et al. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Int J Cancer 2011; 129: 1761-1772.
67. Han A, Chen EH, Niedt G, et al. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol 2009; 145: 792-796.
68. Kaposi M. Zur Nomenklatur des Idiopathische Pigments-arkoms Kaposi. Arch Derm Syphilol 1894; 49: 133-136.
69. Kaposi M. Idiopathic multiple pigmented sarcoma of the skin. CA Cancer J Clin 1982; 32: 342-347.
70. Schwartz RA, Micali G, Nasca MR, et al. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol 2008; 59: 179-206.
71. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal transplant recipients. N Engl J Med 2005; 352: 1317-1323.
72. Mbulaiteye SM, Engels EA. Kaposi's sarcoma risk among transplant recipients in the United States (1993-2003). Int J Cancer 2006; 119: 2685-2691.
73. Shepherd FA, Maher E, Cardella C, et al. Treatment of Kaposi's sarcoma after solid organ transplantation. J Clin Oncol 1997; 15: 2371-2377.
74. Beral V, Peterman TA, Berkelman RL, et al. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? Lancet 1990; 335: 123-128.
75. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266: 1865-1869.
76. Mesri EA, Cesarman E, Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nat Rev Cancer 2010; 10: 707-719.
77. Gallo RC. The enigmas of Kaposi's sarcoma. Science 1998; 282: 1837-1839.
78. Montaner S, Sodhi A, Molinolo A, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003; 3: 23-36.
79. Grisotto MG, Garin A, Martin AP, et al. The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J Clin Invest 2006; 116: 1264-1273.
80. Ma T, Jham BC, Hu J, et al. Viral G protein-coupled receptor upregulates angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. Proc Natl Acad Sci U S A 2010; 107: 14363-14368.
81. Sodhi A, Montaner S, Patel V, et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor upregulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000; 60: 4873-4880.
82. Leitch H, Trudeau M, Routy JP. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy. HIV Clin Trials 2003; 4: 107-114.
83. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004; 22: 399-402.
84. Campistol JM, Schena FP. Kaposi's sarcoma in renal transplant recipients - the impact of proliferation signal inhibitors. Nephrol Dial Transplant 2007; 22(Suppl. 1): 17-22.
85. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534.
86. Lebbe C, Euvrard S, Barrou B, et al. Sirolimus conversion for patients with post-transplant Kaposi's sarcoma. Am J Transplant 2006; 6: 2164-2168.
87. Wasywich CA, Croxson MC, van Doornum GJ, et al. Sirolimus for Kaposi's sarcoma. J Heart Lung Transplant 2006; 25: 726-729.
88. Colegio OR, Leffell JD. Genetics of Skin Cancer. In: Rigel DS, Robinson JK, Ross MI, et al., eds. Cancer of the Skin, 2nd edn. Philadelphia, PA: Elsevier Saunders 2011; 12-22.
89. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17: 2502-2511.
90. Informa Healthcare. Litt's drug eruptions and reactions manual. London: Informa Healthcare 2012. http://www.drugeruptiondata.com/. [Accessed February 18, 2012.]
91. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002; 346: 683-693.
92. Stallone G, Infante B, Grandaliano G, Gesualdo L. Management of side-effects of sirolimus therapy. Tranzrsplantation 2009; 87: 23-26.
93. Kahan B. Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment. Expert Opin Drug Saf 2011; 10: 727-749.